GlassScriptPhysician profile
Bernice V Francis
NPI 1104896976
$3,406.44
in general payments reported to CMS, 2019-2025
29 companies · $255 in 2025
The $255 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,212 · 2022: $727 · 2023: $675 · 2024: $537 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,467.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $664.18 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $474.19 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $438.57 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Abbvie INC. | $351.78 | 2021-2025 | |
| Pfizer INC. | $232.86 | 2021-2025 | |
| Esperion Therapeutics, INC. | $157.12 | 2021-2022 | |
| Amarin Pharma, INC. | $140.10 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $134.09 | 2021-2023 | Xifaxan |
| Glaxosmithkline, LLC. | $126.95 | 2021-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $84.60 | 2021-2025 | Otezla, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $82.61 | 2021-2025 | Spravato, Xarelto |
| Lilly USA, LLC | $76.16 | 2021-2024 | Zepbound |
| Astellas Pharma US INC | $74.03 | 2021-2024 | Veozah |
| Merck Sharp & Dohme LLC | $52.40 | 2021-2024 | Capvaxive |
| Abbott Laboratories | $48.79 | 2021-2023 | Freestyle Libre 3 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $44.26 | 2023 | Eliquis |
| Boston Scientific Corporation | $23.11 | 2023 | Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $21.27 | 2021 | |
| Vanda Pharmaceuticals INC. | $20.93 | 2021 | |
| Sanofi Pasteur INC. | $19.84 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.32 | 2021 | |
| Dexcom, INC. | $16.42 | 2024 | Dexcom G6 Transmitter |
| Harmony Biosciences LLC | $16.13 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $15.63 | 2022 | |
| Xeris Pharmaceuticals, INC. | $14.86 | 2023 | Keveyis |
| Verona Pharma, INC. | $14.85 | 2025 | Ohtuvayre |
| Kowa Pharmaceuticals America, INC. | $14.61 | 2021 | |
| Nestle Healthcare Nutrition INC. | $14.56 | 2021 | |
| Almatica Pharma LLC | $13.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernice Francis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.